Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review
Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.
Synergy Pharmaceuticals Inc Key Recent Developments
Mar 01,2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
Nov 09,2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results
Oct 17,2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 09,2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update
May 10,2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.
Synergy Pharmaceuticals Inc Key Recent Developments
Mar 01,2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
Nov 09,2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results
Oct 17,2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 09,2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update
May 10,2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Synergy Pharmaceuticals Inc - Key Facts
Synergy Pharmaceuticals Inc - Key Employees
Synergy Pharmaceuticals Inc - Key Employee Biographies
Synergy Pharmaceuticals Inc - Major Products and Services
Synergy Pharmaceuticals Inc - History
Synergy Pharmaceuticals Inc - Company Statement
Synergy Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Synergy Pharmaceuticals Inc - Business Description
R&D Overview
Synergy Pharmaceuticals Inc - Corporate Strategy
Synergy Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Synergy Pharmaceuticals Inc - Strengths
Synergy Pharmaceuticals Inc - Weaknesses
Synergy Pharmaceuticals Inc - Opportunities
Synergy Pharmaceuticals Inc - Threats
Synergy Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
Nov 09, 2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results
Oct 17, 2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 09, 2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update
May 10, 2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
Apr 17, 2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer
Mar 01, 2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Synergy Pharmaceuticals Inc - Key Facts
Synergy Pharmaceuticals Inc - Key Employees
Synergy Pharmaceuticals Inc - Key Employee Biographies
Synergy Pharmaceuticals Inc - Major Products and Services
Synergy Pharmaceuticals Inc - History
Synergy Pharmaceuticals Inc - Company Statement
Synergy Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Synergy Pharmaceuticals Inc - Business Description
R&D Overview
Synergy Pharmaceuticals Inc - Corporate Strategy
Synergy Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Synergy Pharmaceuticals Inc - Strengths
Synergy Pharmaceuticals Inc - Weaknesses
Synergy Pharmaceuticals Inc - Opportunities
Synergy Pharmaceuticals Inc - Threats
Synergy Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
Nov 09, 2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results
Oct 17, 2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 09, 2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update
May 10, 2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
Apr 17, 2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer
Mar 01, 2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Synergy Pharmaceuticals Inc, Key Facts
Synergy Pharmaceuticals Inc, Key Employees
Synergy Pharmaceuticals Inc, Key Employee Biographies
Synergy Pharmaceuticals Inc, Major Products and Services
Synergy Pharmaceuticals Inc, History
Synergy Pharmaceuticals Inc, Subsidiaries
Synergy Pharmaceuticals Inc, Key Competitors
Synergy Pharmaceuticals Inc, Ratios based on current share price
Synergy Pharmaceuticals Inc, Annual Ratios
Synergy Pharmaceuticals Inc, Annual Ratios (Cont...1)
Synergy Pharmaceuticals Inc, Interim Ratios
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Synergy Pharmaceuticals Inc, Key Facts
Synergy Pharmaceuticals Inc, Key Employees
Synergy Pharmaceuticals Inc, Key Employee Biographies
Synergy Pharmaceuticals Inc, Major Products and Services
Synergy Pharmaceuticals Inc, History
Synergy Pharmaceuticals Inc, Subsidiaries
Synergy Pharmaceuticals Inc, Key Competitors
Synergy Pharmaceuticals Inc, Ratios based on current share price
Synergy Pharmaceuticals Inc, Annual Ratios
Synergy Pharmaceuticals Inc, Annual Ratios (Cont...1)
Synergy Pharmaceuticals Inc, Interim Ratios
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Synergy Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Synergy Pharmaceuticals Inc, Performance Chart (2013 - 2017) 26
Synergy Pharmaceuticals Inc, Ratio Charts 28
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30
COMPANIES MENTIONED
Valeant Pharmaceuticals International Inc
Takeda Pharmaceuticals America Inc
Sucampo Pharmaceuticals Inc
Shire Plc
Ocera Therapeutics Inc
Ironwood Pharmaceuticals Inc
AstraZeneca Plc
Allergan Plc
Synergy Pharmaceuticals Inc, Performance Chart (2013 - 2017) 26
Synergy Pharmaceuticals Inc, Ratio Charts 28
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30
COMPANIES MENTIONED
Valeant Pharmaceuticals International Inc
Takeda Pharmaceuticals America Inc
Sucampo Pharmaceuticals Inc
Shire Plc
Ocera Therapeutics Inc
Ironwood Pharmaceuticals Inc
AstraZeneca Plc
Allergan Plc